Our understanding of the molecular pathways that control immune responses, particularly immunomodulatory molecules that control the extent and duration of an immune response, have led to new approaches in the field of transplantation immunology to induce allograft survival. These molecular pathways are being defined precisely in murine models and translated into clinical practice; however, many of the newly available drugs are human-specific reagents. Furthermore, many species-specific differences exist between mouse and human immune systems. Recent advances in the development of humanized mice, namely, immunodeficient mice engrafted with functional human immune systems, have led to the availability of a small animal model for the study of human immune responses. Humanized mice represent an important preclinical model system for evaluation of new drugs and identification of the mechanisms underlying human allograft rejection without putting patients at risk. This review highlights recent advances in the development of humanized mice and their use as preclinical models for the study of human allograft responses.
Abbreviations: anti-Gr1, anti-granulocyte antibody; anti-GM1, anti-monosialotetrahexosylganglioside 1; BAFF, B cell activating factor; beige, Lyst bg ; BLT, transplantation with fetal liver and thymus and injection of autologous liver hematopoietic stem cells; BRG, C.Cb-Rag2 tm1Fva IL2rg tm1Sug ; CTLA4, cytotoxic T lymphocyte associated protein 4; ESC, embryonic stem cell; GVHD, graft-versus-host disease; HSC, hematopoietic stem cell; Hu-PBL-SCID, transplantation with human peripheral blood mononuclear cells; Hu-SRC-SCID, transplantation with human CD34 þ hematopoietic stem cells; IFN-g, interferon-g; IL2rg null , IL-2 receptor common gamma chain knockout; iPSC, induced pluripotent stem cell; MST, median survival time; NICC, neonatal porcine islet cell cluster; NOG, NOD.Cg-Prkdc scid IL2rg tm1Sug Introduction MHC-mismatched grafts induce the activation of a cellmediated immune response that leads to graft rejection in the absence of immunosuppressive therapy. As the technology for transplanting cells and tissues has improved, the major remaining limiting factor influencing the success of an organ transplant is the ability to control this immune response. Understanding the mechanisms of allograft rejection is imperative for developing new immune therapies to improve the long-term success of organ transplants. Mouse models of allogeneic rejection have provided insights that have led to the development of several new immunosuppressive and immunomodulatory approaches. Nevertheless, successful immunotherapies in animal models, when translated into the clinic, have produced limited success to date, likely in part because of the many species-specific differences between mouse and human immune responses (1) . An important additional difference is the presence of memory T cells in humans that are potentially alloreactive (2) (3) (4) and that are absent in na€ ıve mice housed in microisolator cages in specific pathogen-free facilities and explicitly not exposed to viral infections.
Recent advances in the development of humanized mice have positioned them as an excellent preclinical model to investigate species-specific molecules, molecular pathways and mechanisms underlying human allograft rejection and to investigate and evaluate potential therapies without putting patients at risk. This review outlines these recent advances and the use of humanized mice for the study of transplantation. 
Engraftment approaches
There are three standard approaches to engrafting a human immune system into immunodeficient mice. Mice can be humanized by the injection of human peripheral blood mononuclear cells (PBMCs), HSCs or HSCs in combination with implantation of autologous fragments of fetal thymus and liver. The injection of human PBMCs into immunodeficient mice, also known as the Hu-PBL-SCID model, leads to the engraftment primarily of T cells (5) (6) (7) (8) . Hu-PBL-SCID mice develop a xenogeneic graft-versus-host-like disease (GVHD) within a few weeks, but this model can be used for short-term studies to examine T cell rejection of human allografts (9) . The injection of CD34 þ HSCs into newborn or young mice, also known as the Hu-SRC-SCID model, allows for the differentiation and development of a more complete immune system including T cells, B cells and innate immune cells. HSCs can be sourced from human bone marrow, umbilical cord blood (UCB), fetal liver or granulocyte colony-stimulating factor mobilization of HSCs into the blood. The major limitation of this model is that the human T cells are selected and educated on mouse MHC within the host thymus and thus are H2 restricted, leading to complex interactions of T cells and antigen-presenting cells in the murine host during the development of an immune response. To improve this model, human fetal thymus can be surgically implanted under the kidney capsule of adult conditioned mice, which are then injected with CD34
þ HSCs isolated from the autologous fetal liver (10) (11) (12) . This enhances the immune system because T cells that develop are HLA restricted. This is the most robust human immune system engraftment protocol currently available (5-7). Human skin allografts Allogeneic rejection of human allografts by humanized mice has been studied for >20 years, and this literature was reviewed recently by us (13) and others (8) . Early studies with the Hu-PBL-SCID model using CB17-scid mice led to inconsistent results due to poor human T cell engraftment, which was improved by elimination of host NK cells using anti-monosialotetrahexosylganglioside 1 (anti-GM1) antibody or addition of the Lyst bg (beige) mutation to the CB17-scid strain (8, 13) . Using CB17-Lyst bg Prkdc scid (SCID/ beige) mice led to the conclusion that human CD4 and CD8 T cells were both important in skin allograft rejection (14, 15) , and that was confirmed using NOD.CB17 Prkdc scid b2m
null (NOD-scid b2m null ) mice (16) . Transitioning to NSG mice, which achieve high levels of human cell engraftment, it was observed that they needed to be treated with rat antimouse granulocyte (anti-Gr1) antibody after skin transplantation for successful healing of the graft due to the infiltration of mouse innate immune cells (9) . Skin grafts on NSG mice treated with anti-Gr1 mAb heal and exhibit excellent vascularization and morphology. In the Hu-PBL-SCID model using NSG mice, 100% of allografts are rejected within 21 days, providing a robust and reproducible model for study of human T cell-mediated skin allograft rejection (9) .
Further studies characterizing skin allograft-infiltrating T cells documents the presence of human CD4 and CD8 T cells producing IL-17A in the graft dermis and epidermis (17) . IL-17A has strong inflammatory properties and has been associated with psoriasis (18) (19) (20) and atopic dermatitis (21) . T regulatory cells (Tregs) are a major player in immunoregulation, and CD4 þ FoxP3 þ T cells are present in the basal layer of skin grafts on SCID/beige mice after PBMC injection, suggesting an attempt by the immune system to downmodulate the immune inflammation (17) .
Human islet allografts
Islet transplantation has been used to successfully restore glucose homeostasis in patients with type 1 diabetes, but most patients subsequently lose insulin independence over time, and the procedure comes with adverse side effects, predominantly due to the use of immunosuppressive drugs to prevent graft rejection (22) . Humanized mouse models are becoming a valuable tool to study the mechanisms of islet allograft rejection and to test potential therapeutics prior to their advancement to the clinic.
The Hu-PBL-SCID model has been used to study islet rejection, but there is a ''race'' between the rejection of the islets and the development of GVHD, making long-term monitoring for therapeutic interventions difficult (23) . Islet transplantation into humanized mice has been ongoing for %25 years; however, prior to the development of NSG mice, T cell engraftment and islet rejection were variable and required complex approaches to achieve complete rejection (8, 13) . Simultaneous injection of allogeneic PBMCs with islet grafts into NSG mice results in rapid graft rejection and return to hyperglycemia within 21 days in 100% of mice (24) . When islet grafts were allowed to become established in diabetic NSG mice for 37 days prior to allogeneic PBMC injection, the return to hyperglycemia occurred in two of three mice before the termination of the study, due to the development of GVHD (24) .
The Hu-SRC-SCID model develops a more complete immune system but is limited by the selection of human T cells on mouse MHC. NSG and BRG HSC-engrafted mice have shown contrasting results when transplanted with allogeneic human islets. HSC-engrafted hyperglycemic BRG mice are not able to reject human islets and exhibit minimal T cell infiltration into the graft (25) . In contrast, hyperglycemic HSC-engrafted NOD-Rag1 tm1Mom IL2g null Ins2 Akita (NRG-Akita) mice engrafted with 5 Â 10 4 UCBderived CD34
þ HSCs were shown to reject %60% of human islet allografts, with evidence of strong mononuclear cell infiltration into the rejecting grafts (26) . In those mice that did not revert to hyperglycemia, a mononuclear infiltrate into the graft was still observed.
In a more recent study following injection of higher numbers of UCB-derived CD34 þ HSCs (2 Â 10 5 ) into NSG mice, all of the islet grafts were rejected within 17 days after transplantation, as shown by the return to hyperglycemia (27) . Graft rejection in NSG mice was confirmed by the loss of histological staining for human insulin and was associated with infiltration of human CD4 T cells, macrophages and neutrophils. Interestingly, in this model, very few CD8 T cells were found to infiltrate the graft, which is in contrast to Hu-PBL-SCID models. Of particular interest in this report is that injection of 6 Â 10 6 ex vivo expanded human Tregs completely prevented islet graft rejection (27) . A more complete comparison of these three different HSCengrafted models of islet allograft rejection is provided in Table 2 . The differences in the rejection of human islets in these models may be due to differences in the host strain or in the numbers of human HSCs used for engraftment, leading to differences in human immune function in these models.
Human cardiac tissue
The endothelial cells lining arterial grafts are immunogenic and have been shown to activate allogeneic human T cells (28) . Many of the studies relating to cardiac grafts in humanized mice were performed in humanized SCID/beige mice due to the high sensitivity of NSG mice to paralysis and/or death after human artery transplantation (29) . The majority of SCID/beige mice receiving artery transplants followed by allogeneic PBMCs exhibit enhanced infiltration of human cells into the graft and histological changes consistent with rejection (30) . The extensive study of this model has revealed several mediators of graft injury that have possible therapeutic potential. Infiltrating T cells produce interferon-g (IFN-g) (31), which sustains enhanced HLA-DR expression on endothelial cells lining the graft and induces neointima, or scarring of the inner most layer of the blood vessels within the human arterial graft (32) . Neutralization of IFN-g blocks rejection of grafts by infiltrating T cells (31) . Arterial graft pretreatment with rapamyacin reduces graft injury and the number of T cells that infiltrate into the intima (33) . This protection from graft injury is mediated by the upregulation of programmed death ligand 1 (PD-L1) and 2; conversely, blockade of programmed cell death 1 increases graft injury (33) , suggesting that an immunomodulatory approach to prevent arterial graft rejection may be effective.
Alternatively, blockade of transforming growth factor b (TGF-b) enhances graft injury (34) . TGF-b is produced by the arterial graft and reduces the ability of the infiltrating allogeneic T cells to produce IFN-g. Moreover, proinflammatory cytokines IL-1 and IL-6 produced from the arterial graft appear to promote graft injury (35, 36) . IL-6-blocking antibody reduces graft injury, with a reduction in total vessel area and the intimal area and increased lumen area (37) . A similar reduction of graft injury was found using a human-specific IL-1R antagonist, accompanied by reduced infiltration of human immune cells and decreased IL-17 production. These studies suggest that arterial grafts produce cytokines that both protect and enhance allogeneic immune responses. Using the Hu-SRC SCID/ beige humanized mouse model, which has poor engraftment of T and B cells, human arterial grafts showed graft injury with the formation of neointimas that contained macrophages but no CD3-, CD11c-, or CD19-positive cells, suggesting a role for macrophages in arterial graft injury (29) .
Pluripotent stem cells and stem cell-derived cell populations A new area of transplantation biology is the use of mature cell populations differentiated from pluripotent stem cells. The major question involved in these transplantations is whether the pluripotent stem cells and their differentiated progeny are susceptible to autologous or allogeneic immune responses. In the murine system, it has been reported that differentiated cells from induced þ umbilical cord blood HSCs and human islets. HSC, hematopoietic stem cell; UCB, umbilical cord blood. Ã The derivation of the BRG strain, the origin of the Rag2 null mutation and the origin of the IL2rg null mutation were not reported.
pluripotent stem cells (iPSCs) elicit immune responses when transplanted into syngeneic hosts (38) . In contrast, a recent report suggested that differentiated cells derived from iPSCs fail to elicit an immune response in syngeneic murine hosts (39) . Understanding the immunogenicity of human cells and tissues derived from iPSCs or embryonic stem cells (ESCs) will be an important consideration as this cellular therapy progresses toward clinical trials.
Using the NSG mouse engrafted with human fetal liver and thymus and injected with autologous liver CD34 þ HSCs (BLT model), it was shown that allogeneic teratomas derived from human ESCs are heavily infiltrated with immune cells; regress in size; and, after 6 weeks, consist mostly of liquid cysts, suggesting they are being rejected (38) . Similarly, human ESCs differentiated into fibroblasts or cardiomyocytes and transplanted subcutaneously or intramuscularly, respectively, into NSG-BLT mice became necrotic and infiltrated with human immune cells. To prevent injury of transplanted human ESCs and their differentiated fibroblasts or cardiomyocytes, the human ESCs were genetically engineered to express cytotoxic T lymphocyte associated protein 4 (CTLA4) Ig and PD-L1, which modulate T cell costimulatory pathways. ESC teratomas and differentiated fibroblasts and cardiomyocytes expressing these molecules were effectively protected from human immune infiltration in NSG-BLT mice (40) . It must be cautioned, however, that relying solely on the presence or absence of human T cell infiltration is not a sufficient measure of graft rejection because infiltrates, in fact, may be suppressing the immune response (39) .
The ability of costimulation blockade to protect iPSCderived beta cells from both xenogeneic and allogeneic rejection has been reported (41) . Human iPSC-derived beta cells are rapidly rejected when transplanted into immunocompetent mice. Similarly, human iPSC-derived beta cells are also rejected in NSG mice injected with 15 Â 10 6 allogeneic human PBMCs (41) . In contrast, both xenograft and allogeneic rejection are prevented when the mice are treated with the costimulation blockade agents CTLA4 Ig plus anti-CD154 (anti-CD40L) antibody (41) . These data combined with previous reports suggest that iPSC-derived cells and tissues can be rejected by allogeneic human immune systems but that this rejection can be prevented by costimulation blockade.
Human Tregs and mesenchymal stem cells as regulatory cells
The ability to evaluate the in vivo efficacy of human regulatory populations to prevent graft rejection in humanized mice clearly has advantages as a test for their functional capability and as a model that allows the optimization of the source and ex vivo expansion protocols for human regulatory cells. Nevertheless, as shown by the approaches described below, the choice of the immunodeficient strain, allograft target, human immune engraftment approach, definition of successful immune ''engraftment'' and evaluation of immune rejection, and the efficacy of the regulatory population in preventing rejection of allografts are not well defined and are ''model and system'' dependent. Depending on the recipient strain and model system, 5-300 Â 10 6 effector PBMCs are required for infiltration and damage to the target graft.
In BRG mice transplanted with human aortic grafts and injected with 10 Â 10 6 PBMCs with or without 1-2 Â 10 6
Tregs, it was observed that the addition of Tregs could prevent the development of transplant arteriosclerosis when studied histologically 30 days later (42) . Graft preservation was associated with a decrease in the secretion of IFN-g. In BRG mice engrafted with human skin for 35 days, injection of 5 Â 10 6 human PBMCs (engraftment of human PBMCs defined as >1% human CD45 þ cells in the spleen) led to rejection, with a median survival time (MST) of 34-40 days (43) . Interestingly, in this report, the authors also showed that skin grafts survived for >100 days following injection of PBMCs autologous to the skin graft (i.e. from the same donor), highlighting that the rejection appeared to be an allogeneic and not a nonspecific immune response. When allogeneic PBMCs were mixed with ex vivo expanded Tregs at a 1:1 ratio prior to injection, no skin graft rejection was observed up to 100 days (the duration of the experiment) (43) . Recently, the ability of Tregs to prevent allograft rejection was extended to islet allografts using similar approaches (44) . In this study, a high number of human islets (8000 islet equivalents) were transplanted into BRG mice for 14 days, followed by injection of 40 Â 10 6 PBMCs with or without an equal number of ex vivo expanded Tregs. Islet allografts receiving only allogeneic PBMCs were rejected with an MST of 23 days, but when an equal number of Tregs were coinjected, MST was >45 days, with only two of the 13 mice receiving Tregs rejecting the grafts (44) .
In a similar study using NSG or BRG mice engrafted with human skin for 4-6 weeks and injected with 5 Â 10 6 PBMCs with or without coinjection of 1 Â 10 6 Tregs (engraftment defined as >0.5% human CD45 þ splenic cells), allospecific Tregs were found to be more potent inhibitors of skin graft rejection than polyclonal expanded Tregs (45) . In an extension of this study, a method to generate clinical-grade allospecific Tregs was described, and again, these allospecific Tregs transplanted into BRG mice with human skin grafts were found to be more potent inhibitors of graft injury than polyclonal expanded Tregs under very similar conditions but with increased numbers of PBMCs (10 Â 10 6 ) and Tregs (2 Â 10 6 ) (46). Graft injury in both studies was evaluated at 4 weeks after PBMC injection and consisted of analyses of human CD45 infiltration, Ki67 and involucrin staining, expression of terminal transferase-mediated dUTP nick end labelingpositive nuclei in dermal infiltrates, preservation of human CD31 staining, and detection of CD4 þ FoxP3 þ Tregs.
Overall graft survival was not reported in either study (45, 46) .
In a variation of this approach, CB17-scid mice were transplanted with human skin grafts, and 6 weeks later, anti-asialo GM1 antibody was administered to deplete murine host NK cells, followed by injection of 300 Â 10 6 allogeneic PBMCs. Complete rejection of the graft was not observed, but addition of bone marrow or adipose-derived mesenchymal stem cells as an immunoregulatory population to the allogeneic PBMCs led to decreased leukocyte infiltration into the graft and reduced expression of inflammatory cytokines such as IFN-g, tumor necrosis factor a, IL-1b and IL-6 (47). These studies suggest that humanized mice can be used to evaluate the ability of human regulatory cells to modulate allograft rejection, but the results show that variations in the approach may influence the data generated.
Xenografts
Xenograft transplantation using porcine grafts provides a potentially unlimited source for donor tissues if the xenograft rejection process could be overcome. Humanized mice have been used to begin to address the issue of xenograft rejection by human immune systems. In the Hu-PBL-SCID model, diabetic NSG mice were transplanted with 5000 neonatal porcine islet cell clusters (NICCs), which restored normoglycemia (48) . When 1-10 Â 10 6 human PBMCs were injected, the NICC grafts were destroyed in a PBMC number-dependent manner. Graft infiltration could be blocked by the coinjection of ex vivo expanded human Tregs, but that was mediated in part by Treg production of IL-10 (49).
Extending these observations to investigate the ability of central tolerance in the thymus to induce xenograft tolerance, NSG mice were transplanted with a porcine thymus and injected with human CD34 þ HSCs (50) . In this system, human T cells were generated, and they were specifically nonreactive to the murine host, the human HSC donor and the MHC of the porcine donors. Skin grafts from porcine donors sharing the MHC of the thymus were not rejected, whereas skin grafts from other non-MHCmatched porcine donors were rapidly rejected (50) . These various xenograft models will be valuable tools for the study of human xenograft responses and will accelerate efforts to identify approaches for the induction of xenotolerance and permanent xenograft survival.
Na€ ıve, effector, and memory T cells and alloantibodies in graft survival Humanized mice have also been used to investigate the role of T cells involved in allograft rejection and the role of alloantibodies in graft survival. In early studies in humanized mice, it was shown that memory but not na€ ıve T cells were the principal mediators of skin graft injury and that this destruction could be blocked using a 4-1BB ligand, an ICOS ligand or an OX40 ligand (51) . This was extended to show that CD4 effector/memory T cells but not CD4 central memory T cells targeted endothelial cells in skin grafts, and in vitro analyses indicated that these cells mediated their effect in part by secretion of IFN-g (52) . Immunodeficient mice bearing human skin grafts injected with the anti-HLA rat antibody W6/32 were shown to have activated endothelial cell exocytosis and leukocyte trafficking in the graft, suggesting that alloantibodies may have a role in transplant rejection (53) . This study was extended and showed that, combined with >6 hours of cold ischemia, antibody administration-regardless of specificitypromoted transplant vasculopathy, as demonstrated by intimal expansion in human vessels transplanted into BRG mice (54) . Using an in vitro model system, the binding of anti-HLA antibodies to human aortic, venous and microvascular endothelial cells induced endothelial P-selectin and increased adherence of monocytes, implying a role of alloantibodies in recruitment of monocytes that participate in antibody-mediated rejection of human allografts (55) . This suggestion was confirmed in vivo using a mouse/ mouse transplant model of C57BL/6-Rag1 null recipients of BALB/c cardiac allografts that were passively transferred with donor-specific MHC class I antibodies (56) .
Remaining limitations and future opportunities
Although humanized mice represent exciting new models that permit the direct study of human transplantation in a small animal model without putting patients at risk, limitations remain for the available models.
The development of GVHD in almost all of the model systems represents a constraint on the experimental window available for the study of graft survival, particularly in the Hu-PBL-SCID model system (57); however, much of the xenoreactivity of human immune systems to murine antigens is to the MHC class I and II molecules (57) . In the NSG-BLT model, CD8 T cells, which are reactive to murine MHC class I, appear to have a central role in the development of GVHD symptoms (58) . A recently described model based on the development of B6.129-Rag2 tm1Fwa CD47 tm1fpl IL2rg tm1cgn mice suggests that the lack of murine CD47 decreases the development of GVHD symptoms in BLT humanized mice (59) . Development of immunodeficient hosts deficient in murine MHC and/or CD47 may decrease the development of GVHD symptoms and extend the experimental window available for the study of transplantation.
Additional opportunities to improve humanized mouse models include optimizing models for enhanced humoral responses, memory T cell formation, lymphoid structures and germinal center formation, which were recently reviewed extensively (5, 60) . Due to the lack of reactivity between many murine cytokines and human cells, additional improvements in the murine host-focusing on the provision of species-specific human cytokines important in human immune development-are under way in a number of laboratories (5-7). Mouse B cell activating factor (BAFF; also termed B lymphocyte stimulator), for example, binds to but does not signal human B cells (61) , and efforts are under way to generate human BAFF transgenic mice in our laboratory to determine whether this will improve human B cell responses to immunization. Nevertheless, recent reports on transgenic generation of various human species-specific cytokines suggest caution because these factors are expressed in the murine host. Murine IL-2, for example, does not cross-react with human T cells, and transgenic expression of human IL-2 in NOG mice leads to robust human NK cell development at the expense of the other immune cell populations (62) . In BRG mice, transgenic expression of human thrombopoietin, IL-3, granulocyte macrophage colony-stimulating factor, macrophage colony-stimulating factor and signal-regulatory protein a leads to robust human innate immune development, but the experimental window of this strain is relatively limited (63) . Additional modifications of the murine host to reduce macrophages and granulocyte populations will likely be important to achieve circulation of human red blood cells, granulocytes and platelets, which circulate at only low levels in the currently available models of humanized mice (5-7).
Transgenic expression of human HLA class I and II molecules has also been shown to enhance development of HLA-restricted T cell responses in the Hu-SRC-SCID model. HLA-A2 transgenic NSG mice engrafted with HLA-A2 HSCs, for example, have been shown to generate HLA-A2-restricted Epstein-Barr virus (EBV)-specific cytotoxic T cells in humanized mice (64, 65) . Extension of the use of human immune engrafted HLA-Tg immunodeficient mice to allograft rejection has not been reported. Using EBVinfected mice and/or the HLA-restricted cell lines that have been reported (66) may be an approach to study the role of human memory cells in allograft rejection, an area of investigation that has not been pursued to date in humanized mice.
The current models of humanized mice have limited B cell maturation with low antibody levels and deficiencies in their ability to isotype switch following exposure to antigen, resulting in few or no human IgG antibody responses following immunization. Two groups, however, have reported that engraftment of human HLA-DR4 transgenic NRG/NOG mice with HSCs from HLA-DR4 donors leads to improved human IgG production following immunization (67, 68) . Although the available models of humanized mice likely would generate only poor and predominately IgM alloantibody responses to tissue grafts, the injection of human serum containing known alloantibodies into humanized mice might be an approach to study the role of alloantibodies in graft rejection in this model system.
Conclusions
Exciting new models of humanized mice to study transplant rejection are becoming available to the research community. Improvements in immune system engraftment, immune function and the potential for development human myeloid cells, an important component of allograft rejection, are under development. The use of humanized mice as a model for the study of human immune rejection of allografts and xenografts may provide novel insights into the mechanisms responsible for graft rejection and permit rapid evaluation of new approaches to prevent graft loss in transplant recipients.
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